Alector, Inc.
NASDAQ:ALECBiotechnology
+$0.08 today
- Market cap
- $381.13M
- Beta
- 0.59
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.13
Volume 1.27M
Average 0.65M
ALEC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Alector, Inc.NASDAQ: ALEC
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $17.86M fell 52.9% year over year, behind the -37.7% change in trailing-twelve-month research & development. Sequentially, it fell 45.0% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.
Context
- Research & development amounted to 584.8% of revenue in FY2025, up 376.7 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -52.9% toward the trailing-twelve-month pace of -37.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 123.07M USD
- Year-over-year change
- -41.2%
- 4-year CAGR
- -10.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 123.07M | -41.2% |
| FY2024 | 2024-12-31 | 209.24M | +8.9% |
| FY2023 | 2023-12-31 | 192.12M | -8.7% |
| FY2022 | 2022-12-31 | 210.42M | +11.1% |
| FY2021 | 2021-12-31 | 189.41M | — |
Research & Development vs competitors
How ALEC compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -37.7% is the lowest of 9, against a peer median of -4.4%.
- Research & development amounts to 622.7% of revenue for ALEC, versus a peer median of 934.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $312.43M USD | +226.5% | +70.8% | — | |
| LTM Mar 2026 | $114.68M USD | -37.7% | -16.4% | 622.7% | |
| LTM Mar 2026 | $100.48M USD | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $96.1M USD | -9.9% | +48.0% | — | |
| LTM Mar 2026 | $88.91M USD | -7.1% | -0.2% | — | |
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| LTM Mar 2026 | $58.35M USD | -32.7% | +9.5% | — | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M USD | +11.2% | +29.0% | 279.0% |
| Peer median (excluding ALEC) | — | -4.4% | +19.3% | 934.9% | |
Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 207.09M | 133.62M | 97.06M | 100.56M | 21.05M |
| Cost of Revenue | 189.41M | 0 | 8.85M | 185.94M | 9.66M |
| Gross Profit | 17.68M | 133.62M | 88.21M | (85.38M) | 11.38M |
| Gross Margin | 8.5% | 100.0% | 90.9% | -84.9% | 54.1% |
| Research & Development | 189.41M | 210.42M | 192.12M | 209.24M | 123.07M |
| Selling, General & Admin | 55.04M | 61.03M | 56.69M | 57.41M | 53.99M |
| Operating Expenses | 55.04M | 271.45M | 239.95M | 59.62M | 157.19M |
| Depreciation & Amortization | 8.32M | 8.47M | 8.85M | 8.84M | 9.66M |
| EBITDA | (28.01M) | (121.58M) | (116.33M) | (110.08M) | (133.1M) |
| EBITDA Margin | -13.5% | -91.0% | -119.9% | -109.5% | -632.5% |
| Operating Income | (37.36M) | (137.83M) | (151.74M) | (145M) | (145.81M) |
| Operating Margin | -18.0% | -103.2% | -156.3% | -144.2% | -692.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.03M | 7.78M | 26.56M | 26.08M | 3.05M |
| Income Before Tax | (36.33M) | (130.06M) | (125.18M) | (118.92M) | (142.76M) |
| Pre-Tax Margin | -17.5% | -97.3% | -129.0% | -118.3% | -678.4% |
| Income Tax Expense | 0 | 3.25M | 5.21M | 128K | 168K |
| Net Income | (36.33M) | (133.31M) | (130.39M) | (119.05M) | (142.93M) |
| Net Margin | -17.5% | -99.8% | -134.3% | -118.4% | -679.2% |
| EPS (Basic) | (0.45) | (1.62) | (1.56) | (1.23) | (1.39) |
| EPS (Diluted) | (0.45) | (1.62) | (1.56) | (1.23) | (1.39) |
| Weighted Avg Shares | 80.42M | 82.47M | 83.73M | 96.59M | 103M |
| Weighted Avg Shares (Diluted) | 80.42M | 82.47M | 83.73M | 96.59M | 103M |
Alector, Inc.
NASDAQ:ALEC
Intrinsic Alpha fair value
Locked
Current Price
$2.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.